Cargando…

Treatment Approaches for First Episode and Early-Phase Schizophrenia in Adolescents and Young Adults: A Delphi Consensus Report from Europe

PURPOSE: Although first-episode psychosis (FEP) in youth, particularly early-onset schizophrenia (EOS), is managed similarly to adult-onset schizophrenia, few antipsychotics are approved for people aged 13–18 years. We aimed to explore areas of uncertainty in EOS management and provide evidence-base...

Descripción completa

Detalles Bibliográficos
Autores principales: Correll, Christoph U, Fusar-Poli, Paolo, Leucht, Stefan, Karow, Anne, Maric, Nadja, Moreno, Carmen, Nordentoft, Merete, Raballo, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8843859/
https://www.ncbi.nlm.nih.gov/pubmed/35177905
http://dx.doi.org/10.2147/NDT.S345066
_version_ 1784651356562259968
author Correll, Christoph U
Fusar-Poli, Paolo
Leucht, Stefan
Karow, Anne
Maric, Nadja
Moreno, Carmen
Nordentoft, Merete
Raballo, Andrea
author_facet Correll, Christoph U
Fusar-Poli, Paolo
Leucht, Stefan
Karow, Anne
Maric, Nadja
Moreno, Carmen
Nordentoft, Merete
Raballo, Andrea
author_sort Correll, Christoph U
collection PubMed
description PURPOSE: Although first-episode psychosis (FEP) in youth, particularly early-onset schizophrenia (EOS), is managed similarly to adult-onset schizophrenia, few antipsychotics are approved for people aged 13–18 years. We aimed to explore areas of uncertainty in EOS management and provide evidence-based recommendations to mental health specialists. We used the Delphi methodology to gain knowledge in areas lacking evidence-based strategies. This standardized methodology consists of the development of a questionnaire by content experts, which is then submitted to a broader panel of professionals (panelists) to survey their level of agreement on the topics proposed. MATERIALS AND METHODS: The developed questionnaire covered patient management from diagnosis to maintenance treatment and was administered to a broader panel of specialists across Europe. Based on an analysis of responses received in this first round, the items that needed further insight were submitted to the panel for a second round and then reanalysed. RESULTS: An initial set of 90 items was developed; in round I, consensus was reached for 83/90 items (92%), while it was reached for 7/11 (64%) of the items sent out for rerating in round II. Feedback for rounds I and II was obtained from 54/92 and 48/54 approached experts, respectively. There was broad agreement on diagnostic standards, multimodal approaches and focus on adverse events, but uncertainty in terms of pharmacological strategies (including clozapine) in case of failure and antipsychotic dosing in younger patients. CONCLUSION: Despite knowledge about diagnostic clues and integrated management of EOS, this study highlights the lack of standardization in treating EOS, with safety arguments having a major role in the decision-making process. Targeted clinical trials and systematic dissemination across Europe of current scientific evidence on the value of early intervention services is hoped to contribute to standardized and improved quality care for patients with early-phase psychosis and schizophrenia.
format Online
Article
Text
id pubmed-8843859
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-88438592022-02-16 Treatment Approaches for First Episode and Early-Phase Schizophrenia in Adolescents and Young Adults: A Delphi Consensus Report from Europe Correll, Christoph U Fusar-Poli, Paolo Leucht, Stefan Karow, Anne Maric, Nadja Moreno, Carmen Nordentoft, Merete Raballo, Andrea Neuropsychiatr Dis Treat Original Research PURPOSE: Although first-episode psychosis (FEP) in youth, particularly early-onset schizophrenia (EOS), is managed similarly to adult-onset schizophrenia, few antipsychotics are approved for people aged 13–18 years. We aimed to explore areas of uncertainty in EOS management and provide evidence-based recommendations to mental health specialists. We used the Delphi methodology to gain knowledge in areas lacking evidence-based strategies. This standardized methodology consists of the development of a questionnaire by content experts, which is then submitted to a broader panel of professionals (panelists) to survey their level of agreement on the topics proposed. MATERIALS AND METHODS: The developed questionnaire covered patient management from diagnosis to maintenance treatment and was administered to a broader panel of specialists across Europe. Based on an analysis of responses received in this first round, the items that needed further insight were submitted to the panel for a second round and then reanalysed. RESULTS: An initial set of 90 items was developed; in round I, consensus was reached for 83/90 items (92%), while it was reached for 7/11 (64%) of the items sent out for rerating in round II. Feedback for rounds I and II was obtained from 54/92 and 48/54 approached experts, respectively. There was broad agreement on diagnostic standards, multimodal approaches and focus on adverse events, but uncertainty in terms of pharmacological strategies (including clozapine) in case of failure and antipsychotic dosing in younger patients. CONCLUSION: Despite knowledge about diagnostic clues and integrated management of EOS, this study highlights the lack of standardization in treating EOS, with safety arguments having a major role in the decision-making process. Targeted clinical trials and systematic dissemination across Europe of current scientific evidence on the value of early intervention services is hoped to contribute to standardized and improved quality care for patients with early-phase psychosis and schizophrenia. Dove 2022-02-09 /pmc/articles/PMC8843859/ /pubmed/35177905 http://dx.doi.org/10.2147/NDT.S345066 Text en © 2022 Correll et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Correll, Christoph U
Fusar-Poli, Paolo
Leucht, Stefan
Karow, Anne
Maric, Nadja
Moreno, Carmen
Nordentoft, Merete
Raballo, Andrea
Treatment Approaches for First Episode and Early-Phase Schizophrenia in Adolescents and Young Adults: A Delphi Consensus Report from Europe
title Treatment Approaches for First Episode and Early-Phase Schizophrenia in Adolescents and Young Adults: A Delphi Consensus Report from Europe
title_full Treatment Approaches for First Episode and Early-Phase Schizophrenia in Adolescents and Young Adults: A Delphi Consensus Report from Europe
title_fullStr Treatment Approaches for First Episode and Early-Phase Schizophrenia in Adolescents and Young Adults: A Delphi Consensus Report from Europe
title_full_unstemmed Treatment Approaches for First Episode and Early-Phase Schizophrenia in Adolescents and Young Adults: A Delphi Consensus Report from Europe
title_short Treatment Approaches for First Episode and Early-Phase Schizophrenia in Adolescents and Young Adults: A Delphi Consensus Report from Europe
title_sort treatment approaches for first episode and early-phase schizophrenia in adolescents and young adults: a delphi consensus report from europe
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8843859/
https://www.ncbi.nlm.nih.gov/pubmed/35177905
http://dx.doi.org/10.2147/NDT.S345066
work_keys_str_mv AT correllchristophu treatmentapproachesforfirstepisodeandearlyphaseschizophreniainadolescentsandyoungadultsadelphiconsensusreportfromeurope
AT fusarpolipaolo treatmentapproachesforfirstepisodeandearlyphaseschizophreniainadolescentsandyoungadultsadelphiconsensusreportfromeurope
AT leuchtstefan treatmentapproachesforfirstepisodeandearlyphaseschizophreniainadolescentsandyoungadultsadelphiconsensusreportfromeurope
AT karowanne treatmentapproachesforfirstepisodeandearlyphaseschizophreniainadolescentsandyoungadultsadelphiconsensusreportfromeurope
AT maricnadja treatmentapproachesforfirstepisodeandearlyphaseschizophreniainadolescentsandyoungadultsadelphiconsensusreportfromeurope
AT morenocarmen treatmentapproachesforfirstepisodeandearlyphaseschizophreniainadolescentsandyoungadultsadelphiconsensusreportfromeurope
AT nordentoftmerete treatmentapproachesforfirstepisodeandearlyphaseschizophreniainadolescentsandyoungadultsadelphiconsensusreportfromeurope
AT raballoandrea treatmentapproachesforfirstepisodeandearlyphaseschizophreniainadolescentsandyoungadultsadelphiconsensusreportfromeurope